Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

• by Tim Schlierkamp-Voosen, Markus Barden, Helena Janning, Marcell Kaljanac, Dennis Christoph Harrer, Celine Dreger, Kathrin Hammon, Moritz Ertelt, Clara T. Schoeder, Hólmfridur Rósa Halldórsdóttir, Carlos Rodriguez-Pardo, Sine Reker Hadrup, Simone Thomas, Hinrich Abken

• April 30, 2026

Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

• by

• February 13, 2026

• 12 min

How This Oncologist Helps Patients Weigh the Pros and Cons of Cancer Treatments

A Keck Medicine of USC medical oncologist explains how nuanced thinking and open communication can help doctors find the best match for each patient.

• by

• September 18, 2025

• 5 min

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

• by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

• August 20, 2025